BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 25402820)

  • 21. Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
    Wang YW; Wang SJ; Zhou YN; Pan SH; Sun B
    J Cancer Res Clin Oncol; 2012 May; 138(5):785-97. PubMed ID: 22270965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
    Park JK; Kim Y; Kim H; Jeon J; Kim TW; Park JH; Hwnag YI; Lee WJ; Kang JS
    Oncotarget; 2016 Nov; 7(46):75081-75093. PubMed ID: 27655706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.
    Guo HC; Bu HQ; Luo J; Wei WT; Liu DL; Chen H; Tong HF; Wang ZH; Wu HY; Li HH; Zuo MM; Li W; Lin SZ
    Int J Oncol; 2012 Jun; 40(6):1849-57. PubMed ID: 22378302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer.
    Wang K; Baldwin GS; Nikfarjam M; He H
    Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G632-G640. PubMed ID: 30844294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
    J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
    Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
    Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
    Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
    Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
    Gitto SB; Pandey V; Oyer JL; Copik AJ; Hogan FC; Phanstiel O; Altomare DA
    Mol Pharm; 2018 Feb; 15(2):369-376. PubMed ID: 29299930
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
    Xiang Y; Ye W; Huang C; Yu D; Chen H; Deng T; Zhang F; Lou B; Zhang J; Shi K; Chen B; Zhou M
    Oxid Med Cell Longev; 2018; 2018():2360427. PubMed ID: 29849873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
    Su YH; Hsu TW; Chen HA; Su CM; Huang MT; Chuang TH; Leo Su J; Hsieh CL; Chiu CF
    J Cell Physiol; 2021 Jun; 236(6):4420-4434. PubMed ID: 33184874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
    Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
    Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
    Shimizu K; Nishiyama T; Hori Y
    Pancreas; 2017 Feb; 46(2):268-275. PubMed ID: 28060183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
    Prasad S; Yadav VR; Sung B; Gupta SC; Tyagi AK; Aggarwal BB
    Oncotarget; 2016 Mar; 7(11):13182-96. PubMed ID: 26909608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
    Wang K; Huynh N; Wang X; Baldwin G; Nikfarjam M; He H
    Int J Oncol; 2018 Jan; 52(1):261-269. PubMed ID: 29115428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine.
    Fujisawa T; Nakashima H; Nakajima A; Joshi BH; Puri RK
    Int J Cancer; 2011 Mar; 128(5):1221-31. PubMed ID: 20473925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
    Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
    Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
    J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
    Zhang Z; Duan Q; Zhao H; Liu T; Wu H; Shen Q; Wang C; Yin T
    Cancer Lett; 2016 Nov; 382(1):53-63. PubMed ID: 27576197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.